Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
Choroidal metastases
EGFR mutation
Lung cancer
NSCLC
Targeted therapy
Tyrosine kinase inhibitors
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Dec 2020
03 Dec 2020
Historique:
received:
25
07
2020
accepted:
12
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
13
5
2021
Statut:
epublish
Résumé
Choroidal metastases are the most common eye metastatic site. The prevalence of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to 7% in historical series. Although previously reported, little is known about choroidal metastasis in Epidermal Growth Factor Receptor (EGFR)-mutant Non-small cell lung cancer (NSCLC). This study sought to describe the prevalence of choroidal metastases among patients with EGFR-mutated NSCLC and their characteristics, and to estimate their impact on prognosis. We conducted a single-center retrospective study including all consecutive metastatic EGFR-mutant NSCLC patients, from Sept. 2015 to Oct. 2018. The EGFR-mutant NSCLC patients were identified via the Department of Genetics' files. Patients who exhibited choroidal metastases were compared to patients without choroidal metastases. Kaplan-Meier analysis and log-rank test were conducted to assess median overall survival (OS) from diagnosis for the two groups. The study was approved by the IRB as CEPRO number #2020-010. Prevalence of choroidal metastases in EGFR-mutated NSCLCs was 8.4% (7/83). Five were women, and four current or former smokers. Molecular analysis showed three tumors with exon 19 deletion, three with L858R mutation, and one with complex exon 21 mutation. The choroidal metastases were symptomatic in six/seven patients. Visual disturbances decreased in all but one symptomatic cases upon EGFR TKI, and the choroidal response was maintained over time. Median follow-up was 42.2 mo (95%CI [37.2-47.1]). Median OS in the choroidal metastasis group was 23.4 mo (95%CI [0.1-51.4]) versus 27.9 mo (95%CI [16.9-38.9]) in the non-choroidal metastasis group (p = 0.32). In the choroidal metastasis group, 2-year and 5-year OS were 47.6 and 0%, respectively, versus 55.8 and 26.3% in the non-choroidal metastasis subset. Choroidal metastases in NSCLC EGFR-mutant patients are rare but should be systematically suspected in case of visual disturbance. TKIs are efficient for treating visual symptoms. Whether choroidal metastases confer a worse prognosis remains unclear owing to the third-generation EGFR TKI osimertinib first-line registration.
Sections du résumé
BACKGROUND
BACKGROUND
Choroidal metastases are the most common eye metastatic site. The prevalence of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to 7% in historical series. Although previously reported, little is known about choroidal metastasis in Epidermal Growth Factor Receptor (EGFR)-mutant Non-small cell lung cancer (NSCLC). This study sought to describe the prevalence of choroidal metastases among patients with EGFR-mutated NSCLC and their characteristics, and to estimate their impact on prognosis.
METHODS
METHODS
We conducted a single-center retrospective study including all consecutive metastatic EGFR-mutant NSCLC patients, from Sept. 2015 to Oct. 2018. The EGFR-mutant NSCLC patients were identified via the Department of Genetics' files. Patients who exhibited choroidal metastases were compared to patients without choroidal metastases. Kaplan-Meier analysis and log-rank test were conducted to assess median overall survival (OS) from diagnosis for the two groups. The study was approved by the IRB as CEPRO number #2020-010.
RESULTS
RESULTS
Prevalence of choroidal metastases in EGFR-mutated NSCLCs was 8.4% (7/83). Five were women, and four current or former smokers. Molecular analysis showed three tumors with exon 19 deletion, three with L858R mutation, and one with complex exon 21 mutation. The choroidal metastases were symptomatic in six/seven patients. Visual disturbances decreased in all but one symptomatic cases upon EGFR TKI, and the choroidal response was maintained over time. Median follow-up was 42.2 mo (95%CI [37.2-47.1]). Median OS in the choroidal metastasis group was 23.4 mo (95%CI [0.1-51.4]) versus 27.9 mo (95%CI [16.9-38.9]) in the non-choroidal metastasis group (p = 0.32). In the choroidal metastasis group, 2-year and 5-year OS were 47.6 and 0%, respectively, versus 55.8 and 26.3% in the non-choroidal metastasis subset.
CONCLUSIONS
CONCLUSIONS
Choroidal metastases in NSCLC EGFR-mutant patients are rare but should be systematically suspected in case of visual disturbance. TKIs are efficient for treating visual symptoms. Whether choroidal metastases confer a worse prognosis remains unclear owing to the third-generation EGFR TKI osimertinib first-line registration.
Identifiants
pubmed: 33272243
doi: 10.1186/s12885-020-07630-6
pii: 10.1186/s12885-020-07630-6
pmc: PMC7712981
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186Références
PLoS One. 2016 Jun 13;11(6):e0156728
pubmed: 27294665
Case Rep Ophthalmol Med. 2013;2013:213124
pubmed: 24109538
Arch Soc Esp Oftalmol. 2016 Nov;91(11):551-555
pubmed: 27046001
Cancer Treat Rev. 2014 Dec;40(10):1119-28
pubmed: 25451606
Eur J Ophthalmol. 2010 Sep-Oct;20(5):963-5
pubmed: 20383850
Ophthalmology. 2014 Jan;121(1):352-357
pubmed: 23988200
J Thorac Oncol. 2013 Feb;8(2):e17-8
pubmed: 23328555
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Optometry. 2005 May;76(5):293-301
pubmed: 15884419
Ophthalmology. 1987 Apr;94(4):341-8
pubmed: 3587915
Am J Ophthalmol. 1983 Jun;95(6):788-93
pubmed: 6859188
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Indian J Ophthalmol. 2015 Feb;63(2):122-7
pubmed: 25827542
Surv Ophthalmol. 2011 Nov-Dec;56(6):511-21
pubmed: 22117885
Int Ophthalmol. 2018 Dec;38(6):2669-2675
pubmed: 29071523
Am J Ophthalmol. 2002 Sep;134(3):445-7
pubmed: 12208262
Ophthalmologica. 2009;223(6):411-3
pubmed: 19628953
Ocul Oncol Pathol. 2017 Jan;3(1):28-33
pubmed: 28275600
Ophthalmology. 1997 Aug;104(8):1265-76
pubmed: 9261313
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Respirology. 2008 Mar;13(2):303-5
pubmed: 18339034